Genetic Technologies Strategic Restructure Driving USA Sales Growth
CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader…
Pharmaceuticals, Biotechnology and Life Sciences
CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader…
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 26, 2024 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical…
TOKYO and CAMBRIDGE, Mass., July 26, 2024 (GLOBE NEWSWIRE) — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and…
$8 million grant funds development of NXC-201 in relapsed/refractory AL AmyloidosisLOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) — Nexcella,…
$8 million grant funds development of NXC-201 in relapsed/refractory AL AmyloidosisLOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) — Immix…
Clinical benefit observed among non-small cell lung cancer (NSCLC) patients harboring mutant KRAS (mKRAS) variants in the Phase 2 mecbotamab…
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics…
SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced it will report second quarter…
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or…
VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse…